Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Blood advances·2026
Same author

Safety and feasibility of intermediate-dose post-transplant cyclophosphamide for graft-versus-host disease prophylaxis.

Annals of hematology·2025
Same author

Prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation.

British journal of haematology·2025
Same author

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

JCO oncology practice·2025
Same author

Combined next generation sequencing for HLA typing and chimerism testing.

Human immunology·2025
Same author

Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity.

Cancer immunology, immunotherapy : CII·2025
Same journal

Epigenetic CD4+ T-Cell Quantification from Dried Blood Spots Using a qPCR-Based Assay.

The Journal of molecular diagnostics : JMD·2026
Same journal

Segmental Copy Number Variant Detection Using an Amplicon-based NGS Panel for Integrated Glioma Classification.

The Journal of molecular diagnostics : JMD·2026
Same journal

Clinical Validation of the Roche cobas and cobas 4800 Human Papillomavirus Tests on Self-Collected Vaginal Dry Swabs versus Practitioner-Collected Cervical Specimens Using the VALHUDES Protocol.

The Journal of molecular diagnostics : JMD·2026
Same journal

Long-Read Nanopore Sequencing Enhances BRCA1/2 Variant Detection Compared with Ion Torrent Analysis.

The Journal of molecular diagnostics : JMD·2026
Same journal

Endonuclease-Assisted Selective Exponential Amplification for Ultrasensitive Enrichment and Detection of Low-Abundance Mutant Alleles in Lung Cancer.

The Journal of molecular diagnostics : JMD·2026
Same journal

Validation of NTRK Fusion Detection Using an Ultrarapid, Fully Automated Cartridge-Based PCR Assay.

The Journal of molecular diagnostics : JMD·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.3K

Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism.

Ruoheng Zhang1, Yimeng Shang2, Joseph Cioccio1

  • 1Penn State Cancer Institute, Hershey, Pennsylvania.

The Journal of Molecular Diagnostics : JMD
|November 27, 2024
PubMed
Summary
This summary is machine-generated.

Chimerism testing effectively predicts leukemia relapse after stem cell transplant. Increasing mixed chimerism (IMC) indicates disease activity, but false positives/negatives require careful interpretation for accurate leukemia monitoring.

More Related Videos

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.2K
Trans-inner Cell Mass Injection of Embryonic Stem Cells Leads to Higher Chimerism Rates
05:53

Trans-inner Cell Mass Injection of Embryonic Stem Cells Leads to Higher Chimerism Rates

Published on: May 29, 2018

10.2K

Related Experiment Videos

Last Updated: Jun 6, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.3K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.2K
Trans-inner Cell Mass Injection of Embryonic Stem Cells Leads to Higher Chimerism Rates
05:53

Trans-inner Cell Mass Injection of Embryonic Stem Cells Leads to Higher Chimerism Rates

Published on: May 29, 2018

10.2K

Area of Science:

  • Hematology
  • Oncology
  • Transplant Medicine

Background:

  • Stem cell transplantation is a curative option for hematologic malignancies.
  • Monitoring chimerism post-transplant is crucial for detecting relapse.
  • Increasing mixed chimerism (IMC) serves as an early indicator of disease recurrence.

Purpose of the Study:

  • To evaluate the predictive value of chimerism testing for leukemia relapse.
  • To assess the performance of increasing mixed chimerism (IMC) as a surrogate for disease activity.
  • To analyze the sensitivity and specificity of chimerism monitoring in predicting relapse post-stem cell transplant.

Main Methods:

  • Quantitative PCR and short-tandem repeat methods were combined for high-sensitivity chimerism analysis.
  • A cohort of 184 patients undergoing stem cell transplant for leukemia (AML, ALL, MDS) was studied.
  • 2389 chimerism tests were performed with a median follow-up of 1054 days.

Main Results:

  • A significant increase in relapse risk was observed after one IMC (HR 9.9) or two or more consecutive IMCs (HR 44.4).
  • The predicted relapse probability by day 30 post-IMC was 0% (no IMC), 10% (one IMC), and 40% (≥2 IMCs).
  • Chimerism monitoring demonstrated 86.4% sensitivity and 91.6% specificity for relapse prediction, with identified causes for false positives (T-cell contamination) and false negatives (rapid relapse, extramural relapse).

Conclusions:

  • Chimerism monitoring is a valuable tool for predicting leukemia relapse post-stem cell transplant.
  • Interpreting IMC requires caution due to potential false positives and false negatives.
  • T-cell removal strategies can enhance the specificity of chimerism testing in patients with mixed T-cell chimerism.